- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
3/26/07 11:27 am EDT
New Results Build on Previous Data that Lipitor is the Only Statin to Show an Impact in Head-To-Head Imaging Trials
Separate Analysis Shows Lipitor Cuts the Risk of Coronary Events by Half in Recurrent Stroke PatientsNEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting ofmore...
3/23/07 5:01 pm EDTNEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company’s Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-more...
Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting3/23/07 10:14 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and strokes, and health economics will be presented next week at the American College of Cardiology annual meeting in New Orleans. Atherosclerosis Imaging Trials Three large imaging studies compared Pfizer’s former investigational compoundmore...
3/22/07 1:59 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the company’s U.S. patent covering amlodipine besylate, the active ingredient in Norvasc. Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration. Generic manufacturer Apotex filed the appeal after a lowermore...
3/20/07 3:36 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. Judge John C. Lifland ruled that the patents (Nos. 5,466,823; 5,563,165more...